HIV
Feature
COVID-19 causes major interruption in global HIV progress
“We’ve been set back by COVID but we’ve seen remarkable resilience, a lot of innovation and creativity.”
Feature
NIH on HIV vaccine failure: ‘Get your HIV-negative, at-risk patients on PrEP tomorrow’
From the Journals
TB prevention in people with HIV: How short can we go?
From the Journals
Study: More than half of people taking HIV PrEP discontinue use
From the Journals
Injectable cabotegravir PrEP superior to oral TDF-FTC; trial halted early
“The reason that we were able to show that cabotegravir was superior is because we enrolled a very young, very highly at-risk, very underresourced...
Feature
New guideline for replacement ART: CAB/RPV LA not for everyone
Commentary
Immune reconstitution inflammatory syndrome: ‘Why is my patient getting worse?’
From the Journals
HIV: failed viral suppression in CAB/RPV linked to three risk factors
Conference Coverage
When it comes to young women, regular check-ins support ongoing PrEP use
This is important in the U.S. because cisgender Black women make up 60% of all new HIV cases in the U.S. while accounting for just 14% of the U.S...
Conference Coverage
Two-drug dolutegravir treatment noninferior to 3/4 drug regimen
The fixed-dose dolutegravir-based regimen shows noninferiority versus any ART regimens, while also showing feasibility as a first-line treatment...
Latest News
HIV-associated cryptococcal meningitis: Single-dose regimen found non-inferior
Mortality from cryptococcal meningitis with a single-dose regimen of liposomal amphotericin B is similar to the...